SV2004000109A - Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv - Google Patents
Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-svInfo
- Publication number
- SV2004000109A SV2004000109A SV2000000109A SV2000000109A SV2004000109A SV 2004000109 A SV2004000109 A SV 2004000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2000000109 A SV2000000109 A SV 2000000109A SV 2004000109 A SV2004000109 A SV 2004000109A
- Authority
- SV
- El Salvador
- Prior art keywords
- inhibitors
- combination
- hmg
- lea
- ref
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA INVENCION SE REFIERE AL USO DE UNA COMBINACION DE AL MENOS UN INHIBIDOR DE MTP SELECCIONADO (COMPONENTE A) Y UN INHIBIDOR DE HMG-COA REDUCTASA (COMPONENTE B) PARA LA LUCHA CONTRA ENFERMEDADES DEL SISTEMA CARDIOCIRCULATORIO,A MEDICAMENTOS QUE CONTIENEN ESTA COMBINACION Y A SU OBTENCION.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19929065A DE19929065A1 (de) | 1999-06-25 | 1999-06-25 | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2004000109A true SV2004000109A (es) | 2004-05-07 |
Family
ID=7912459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2000000109A SV2004000109A (es) | 1999-06-25 | 2000-06-23 | Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1196194A2 (es) |
JP (1) | JP2003503342A (es) |
AR (1) | AR028996A1 (es) |
AU (1) | AU5680900A (es) |
CA (1) | CA2376881A1 (es) |
DE (1) | DE19929065A1 (es) |
DO (1) | DOP2000000022A (es) |
GT (1) | GT200000099A (es) |
PE (1) | PE20010302A1 (es) |
SV (1) | SV2004000109A (es) |
UY (1) | UY26218A1 (es) |
WO (1) | WO2001000183A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10030375A1 (de) * | 2000-06-21 | 2002-01-03 | Bayer Ag | Verwendung von MTP-Inhibitoren zur Senkung von ppTRL |
CN1943786A (zh) * | 2002-02-28 | 2007-04-11 | 日本烟草产业株式会社 | 酯化合物及其医药用途 |
WO2005021486A1 (ja) | 2003-08-29 | 2005-03-10 | Japan Tobacco Inc. | エステル誘導体及びその医薬用途 |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
FR2884831B1 (fr) * | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | Methode de criblage de composes inhibiteurs de la mtp |
DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN109053927A (zh) * | 2018-08-08 | 2018-12-21 | 中山大学 | 一种含维生素b12基团的两亲性海藻酸钠衍生物及其制备方法和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4435477A1 (de) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
DE19546918A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclische Heterocyclen |
DE19546919A1 (de) * | 1995-12-15 | 1997-06-19 | Bayer Ag | N-Heterocyclisch substituierte Phenylessigsäure-Derivate |
DE19615265A1 (de) * | 1996-04-18 | 1997-12-04 | Bayer Ag | Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole |
BR9714364A (pt) * | 1996-11-27 | 2000-03-21 | Pfizer | Amidas inibidoras da secreção de apo b/mtp |
CA2286341A1 (en) * | 1997-05-01 | 1998-11-12 | John R. Ii Wetterau | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
-
1999
- 1999-06-25 DE DE19929065A patent/DE19929065A1/de not_active Withdrawn
-
2000
- 2000-06-13 WO PCT/EP2000/005410 patent/WO2001000183A2/de not_active Application Discontinuation
- 2000-06-13 JP JP2001505893A patent/JP2003503342A/ja active Pending
- 2000-06-13 CA CA002376881A patent/CA2376881A1/en not_active Abandoned
- 2000-06-13 EP EP00942056A patent/EP1196194A2/de not_active Withdrawn
- 2000-06-13 AU AU56809/00A patent/AU5680900A/en not_active Abandoned
- 2000-06-21 GT GT200000099A patent/GT200000099A/es unknown
- 2000-06-22 AR ARP000103129A patent/AR028996A1/es unknown
- 2000-06-23 SV SV2000000109A patent/SV2004000109A/es unknown
- 2000-06-23 PE PE2000000625A patent/PE20010302A1/es not_active Application Discontinuation
- 2000-06-23 UY UY26218A patent/UY26218A1/es not_active Application Discontinuation
-
2008
- 2008-04-11 DO DO2000000022A patent/DOP2000000022A/es unknown
Also Published As
Publication number | Publication date |
---|---|
GT200000099A (es) | 2001-12-13 |
PE20010302A1 (es) | 2001-04-12 |
CA2376881A1 (en) | 2001-01-04 |
DOP2000000022A (es) | 2008-08-15 |
WO2001000183A2 (de) | 2001-01-04 |
EP1196194A2 (de) | 2002-04-17 |
WO2001000183A3 (de) | 2001-05-10 |
UY26218A1 (es) | 2001-01-31 |
DE19929065A1 (de) | 2000-12-28 |
AU5680900A (en) | 2001-01-31 |
AR028996A1 (es) | 2003-06-04 |
JP2003503342A (ja) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2000000022A (es) | Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicametos. | |
PA8493401A1 (es) | Uso de inhibidores de cyp2d6 en terapias de combinacion | |
DOP2019000185A (es) | Una formulación sólida de dosificación farmacéutica | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
PA8506101A1 (es) | Uso de un compuesto acat para fabricar una composicion farmaceutica | |
CR7942A (es) | Combinaciones antineoplasticas que comprenden un derivado de rapamicina y un inhibidor de aromatasa | |
PA8513601A1 (es) | Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa | |
HN2002000150A (es) | Agentes antibacteriano | |
PT1328269E (pt) | Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade | |
PT1424893E (pt) | Mistura fungicida que contem derivados de arilamidina. | |
CL2004000416A1 (es) | Compuestos heterociclicos nitrogenados; composicion farmaceutica; y uso del compuesto para tratar o prevenir una condicion mediada por p38, que consiste en una enfermedad inflamatoria, autoinmune, virosica o neurodegenerativa. | |
HN2001000146A (es) | Derivados de pirazol | |
HN2003000227A (es) | Inhibidores de quinasas | |
CL2007000355A1 (es) | Combinacion que comprende un inhibidor de quinasas dependiente de ciclinas, un anticuerpo que inhibe un factor de crecimiento y un agente antimitotico; composicion farmaceutica que la comprende; y su uso para tratar un trastorno proliferativo. | |
GT200000077A (es) | Sal mutua de amlodipino y atorvastatina | |
ECSP044981A (es) | Composicion oftalmica que comprende ascomicina | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
BR0002953A (pt) | Composições e tratamento para complicações diabéticas | |
AR030140A1 (es) | Composiciones derivadas de la 2-piridinamina y metodos relacionados | |
ES2132539T3 (es) | Composiciones insecticidas sinergicas. | |
ES2196559T3 (es) | Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer. | |
SV2003001179A (es) | Formulacion de 2-metilo-tieno-benzodiacepina liofilizada ref. x-11102 | |
BR0002957A (pt) | Combinações de inbidores de aldose-redutase e inibidores de ciclooxigenase-2 seletivos | |
GT200200244A (es) | Composicion intensiva de herbicida | |
IT1318401B1 (it) | Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono. |